Advances in Neoantigen-Based Cancer Vaccines

Area of Science:

• Oncology
• Immunology
• Vaccine Development

Background:

• Neoantigen-based immunotherapies leverage tumor-specific mutations for targeted cancer treatment.
• Neoantigens enable selective T-cell recognition, minimizing off-tumor toxicity.
• Personalized cancer vaccines are emerging as a key therapeutic strategy.

Purpose of the Study:

• To review the landscape of neoantigen vaccines in cancer immunotherapy.
• To compare the immunogenicity and clinical outcomes of different neoantigen vaccine platforms.
• To identify factors influencing vaccine efficacy, such as disease stage and treatment timing.

Main Methods:

• Review of clinical trials and comparative data on peptide, mRNA, and DNA neoantigen vaccines.
• Analysis of T-cell responses (CD8+ and CD4+) elicited by different vaccine types.
• Evaluation of clinical outcomes, including relapse-free survival, in various cancer types.

Main Results:

• Peptide-pulsed dendritic cell (DC) vaccines demonstrate higher CD8+ T cell responses than mRNA vaccines.
• mRNA vaccines may induce CD4+-dominant responses due to immunodominance.
• Clinical trials show robust immune activation and encouraging outcomes in adjuvant settings for melanoma, glioblastoma, and pancreatic cancer.
• Early-stage disease and post-surgical vaccination correlate with better immune responsiveness.

Conclusions:

• Neoantigen vaccines are a promising personalized cancer immunotherapy approach.
• Vaccine platform choice (peptide-DC vs. mRNA) influences T-cell response profiles.
• Optimizing neoantigen prediction, manufacturing, and treatment timing is crucial for future advancements.
• Neoantigen vaccines hold substantial promise for next-generation cancer treatment strategies.